Bayer Aktiengesellschaft (BAYZF)
| Market Cap | 30.20B |
| Revenue (ttm) | 50.34B |
| Net Income (ttm) | -3.52B |
| Shares Out | n/a |
| EPS (ttm) | -3.59 |
| PE Ratio | n/a |
| Forward PE | 5.68 |
| Dividend | 0.13 (0.40%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | n/a |
| Average Volume | 2,783 |
| Open | 30.65 |
| Previous Close | 30.65 |
| Day's Range | 30.65 - 30.65 |
| 52-Week Range | 19.50 - 34.01 |
| Beta | 0.98 |
| RSI | 58.90 |
| Earnings Date | Aug 6, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial numbers in EUR Financial StatementsNews
Court Approves $38M Cash Settlement Against Bayer AG in Hard-Fought Securities Class Action
Following the Bayer-Monsanto merger, litigation has resulted in a valuable settlement that, pending final approval, affirms the rights of ADR investors to
Bayer, Regeneron get EU nod for Eylea's label extension
Bayer's Eylea 8 mg gets EU approval for extended 6-month dosing for macular degeneration & diabetic macular edema. Read more here.
Bayer share price is rising: does it have more upside?
Bayer share price has bounced back this year, making it one of the best-performing companies in the German DAX Index. It has jumped to €26, up by 45% from its lowest point this year.
EY US & Bayer Win “Artificial Intelligence for Good” Award in 2025 AI Breakthrough Awards Program
Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
On Sunday, Exelixis, Inc. (NASDAQ: EXEL) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab . The study includes patients with pr...
Bayer’s stock is charting a 40% rebound after years of losses
Bayer surged almost 40% in 2025, ranking among the DAX’s top performers. The rally has pushed its share price close to surpassing the average 12-month analyst target.
Bayer Files for Approval of gadoquatrane in the U.S.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane f...
Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients
Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected...
Bayer Innovation Procurement Expands Use of Scientist.com's AI-Powered Platform for Global R&D Procurement Orchestration
SAN DIEGO--(BUSINESS WIRE)-- #innovation--Bayer AG Innovation Procurement names Scientist.com as preferred global channel for sourcing external R&D services.
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advan...
Bayer raised to Buy at Goldman after hitting bottom of negative earnings revision cycle
Bayer Crop Science delegation visits ISARC
Bayer Crop Science delegation visits ISARC : A four-member delegation from Bayer Crop Science visited the International Rice Research Institute - Sout.
Bayer subsidiary gains worldwide rights to develop cancer asset VVD-214
Bayer gets FDA nod for Nubeqa in advanced prostate cancer
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
SAN DIEGO & BERLIN, Germany--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, ...
Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Con...
Bayer says new lung cancer therapy granted FDA priority review
Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea
European markets hold steady as traders await fresh cues; Bayer, Philips, SAP on the move
Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals
German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche'...
Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical tr...
Bayer A.G.'s eye disease treatment gets approval in China
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI ...
Bayer Highlights New Data from Oncology and Women's Health Portfolios at 2025 ASCO Annual Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) ...
Bayer CEO on managing through the good and bad: Call out the problems
Bayer CEO Bill Anderson takes the stage at the 2025 CNBC CEO Council Summit to talk to leaders about managing through uncertainty and tackling problems head-on.